Developer docs
API playgroundTry for free, no card

Search company profiles

ab cernelle

Full company profile

uuid02m7crk

Namestring
ab cernelle
Legal namestring
AB Cernelle
Websiteurl
cernelle.se
Company typeenum
Private
Founded yearint
1953
Descriptiontext

AB Cernelle is a Swedish pharmaceutical company founded in 1953 in Ängelholm, specializing in pollen-based pharmaceutical products for male urological conditions, specifically benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company's core technology is the proprietary Cernitin pollen extraction platform developed in 1956, which produces two active pharmaceutical ingredients (APIs): Cernitin T60 (water-soluble dry extract) and Cernitin GBX (fat-soluble soft extract), derived from machine-harvested pollens from organically grown, specially selected plants. These APIs are the active ingredients in a portfolio of branded products including Cernitol (sold in Sweden since 1959), Cernilton (registered in Japan since 1969), Cernitol Novum, Cernilton A, Shenitong, and Pollstimol, with over 2 billion daily doses administered since 1964 and over 40 published clinical trials supporting clinical use. The products are registered as prescription or OTC medicines in Sweden, Japan, Germany, Hungary, Korea, and China, and target urologists and healthcare professionals who treat men over 50 with BPH and men with chronic nonbacterial prostatitis.

Cernelle operates a single GMP-certified manufacturing facility in Ängelholm, Sweden, certified by the Swedish Medical Products Agency and holding Foreign Manufacturer Accreditation from Japanese Health Authorities. Revenue is generated through pharmaceutical product sales via traditional pharmacy and medical provider distribution channels; pricing is not publicly disclosed. Since December 2021, AB Cernelle has operated as a subsidiary of Dermapharm AG, a German diversified pharmaceutical group, which provides access to broader distribution and pharmaceutical expertise while Cernelle retains its own management team and dedicated Swedish operations. The company employs senior leadership drawn from major pharmaceutical firms including AstraZeneca, Pharmacia, Johnson & Johnson, Recipharm, and Kenvue, reflecting deep GMP and regulatory expertise rather than technology or data science capabilities.

The business model is a niche specialty pharma play built on a single proprietary API platform with multi-decade regulatory standing across multiple jurisdictions. There is no public funding history, no disclosed revenue or ARR, and no SaaS or technology component to the offering; the moat is regulatory and process-based rather than data- or AI-driven. Customer concentration risk is moderate given distribution across six country markets with Japan as the historically largest single market.

Short descriptiontext

AB Cernelle is a Swedish pharmaceutical manufacturer, founded in 1953 and now a subsidiary of Dermapharm AG, that develops proprietary pollen-extract APIs (Cernitin T60 and GBX) used in registered drugs such as Cernilton and Cernitol for treating benign prostatic hyperplasia and chronic prostatitis in men, distributed through pharmacies across six countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersÄngelholm, Sweden
HQ citystring
Ängelholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pollen extract pharmaceuticals, benign prostatic hyperplasia treatment, herbal medicinal products, active pharmaceutical ingredients, urological therapeutics
Industry1 code
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Urological Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Products Sales
TypeOne Time License
Description

Cernelle generates revenue through the sale of registered pharmaceutical products Cernilton® and Cernitol® containing Cernitin™ pollen extracts as active pharmaceutical ingredients. Products are sold as prescription and OTC medicines through pharmacies and medical providers worldwide.

cernelle.eu
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Cernitin™
Description

Cernitin™ pollen extracts are the active pharmaceutical ingredients (APIs) manufactured by Cernelle, including Cernitin™ T60 (water soluble dry extract) and Cernitin™ GBX (fat soluble soft extract). These are worldwide registered trademarks belonging to AB Cernelle.

cernelle.eu
+2 more records
Core offering1 text field

AB Cernelle develops and manufactures pollen-based pharmaceutical products for the treatment of male urological conditions, specifically benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company's core offering centers on proprietary Cernitin™ pollen extracts (Cernitin™ T60 water-soluble and Cernitin™ GBX fat-soluble), which serve as active pharmaceutical ingredients in finished dosage-form products such as Cernilton® and Cernitol® sold globally through pharmacy and medical provider channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 40 clinical published trials confirming clinical relevance and efficacy
+3 more records
Product overview1 text field

AB Cernelle is a pharmaceutical company specializing in pollen extract-based pharmaceuticals. The core product portfolio centers on Cernitin™ pollen extracts, two active pharmaceutical ingredients (APIs): Cernitin™ T60 (water-soluble, dry extract) and Cernitin™ GBX (fat-soluble, soft extract). These APIs serve as active ingredients in multiple registered pharmaceutical products including Cernilton® (tablet formulation, registered 1969), Cernitol® (sold in Sweden since 1959), Cernitol® Novum, Shenitong®, Cernilton A®, and Pollstimol®. All products are used for treatment of lower urinary tract symptoms (LUTS) caused by benign prostate diseases including benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company operates GMP-certified manufacturing facilities in Sweden.

Product and service8 records
1Cernitin™ T60
CategoryActive Pharmaceutical Ingredient
Description

Water-soluble, dry pollen extract classified as an active pharmaceutical ingredient (API). Produced from machine-harvested pollens from organically grown, specially selected plants. Used as an API in pharmaceutical products for treating lower urinary tract symptoms caused by benign prostate diseases.

2Cernitin™ GBX
CategoryActive Pharmaceutical Ingredient
Description

Fat-soluble, soft pollen extract classified as an active pharmaceutical ingredient (API). Produced from machine-harvested pollens from organically grown, specially selected plants. Used as an API in pharmaceutical products for treating lower urinary tract symptoms caused by benign prostate diseases.

3Cernilton®
CategoryPharmaceutical Product
Description

Tablet formulation pharmaceutical product containing Cernitin™ pollen extracts as active ingredients. Registered in Japan since 1969 for treatment of chronic prostatitis, chronic pelvic pain syndrome (CP/CPPS), and benign prostate hyperplasia. One of only two pharmaceutical drugs registered worldwide to treat chronic prostatitis and CP/CPPS effectively.

4Cernitol®
CategoryPharmaceutical Product
Description

Pharmaceutical product containing Cernitin™ pollen extracts as active ingredients. Sold in Sweden since 1959 for treatment of chronic prostatitis, chronic pelvic pain syndrome (CP/CPPS), and benign prostate hyperplasia. The Swedish market brand name for the Cernitin™ pollen extract-based product.

5Cernitol® Novum
CategoryPharmaceutical Product
Description

Cernitin™ pollen extract-based pharmaceutical product for treatment of lower urinary tract symptoms caused by benign prostate diseases. Backed by over 40 clinical studies showing good efficacy and tolerability, positioning it as the best-documented plant-based medicine for prostate problems.

6Shenitong®
CategoryPharmaceutical Product
Description

Registered pharmaceutical product containing Cernitin™ pollen extracts as the active ingredient, sold in markets where approved by national health authorities.

7Cernilton A®
CategoryPharmaceutical Product
Description

Registered pharmaceutical product containing Cernitin™ pollen extracts as the active ingredient, sold in markets where approved by national health authorities.

8Pollstimol®
CategoryPharmaceutical Product
Description

Registered pharmaceutical product containing Cernitin™ pollen extracts as the active ingredient, sold in markets where approved by national health authorities.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Italian pharmaceutical company with a strong phytopharmaceutical urology portfolio, including Serenoa repens-based products for BPH. Directly competes with Cernelle as a plant-based BPH specialist in European markets.

TypeBroad incumbent
Description

Global pharmaceutical company that previously marketed Avodart® (dutasteride), a 5-alpha-reductase inhibitor for BPH. Competes broadly with Cernelle in the BPH therapeutics market through mainstream synthetic drug offerings.

TypeDirect peer
Description

German specialty pharmaceutical company focused on urology, marketing both herbal (pumpkin seed extract) and synthetic BPH treatments. Competes with Cernelle in the German-speaking BPH market through similar phytopharmaceutical positioning.

4Strathmann AG
TypeDirect peer
Description

German herbal pharmaceutical company specializing in urology and a subsidiary of Dermapharm AG (Cernelle's parent). Sells plant-based BPH remedies and other urology products, making it a sister-company peer with overlapping botanical-urology positioning and shared distribution within the Dermapharm portfolio.

TypeDirect peer
Description

French pharmaceutical company whose Permixon® (Serenoa repens/saw palmetto extract) is one of the leading plant-based medicines for BPH globally. Directly competes with Cernelle's Cernitol®/Cernilton® in the phytopharmaceutical urology segment and is the most established direct botanical competitor in this indication.

TypeBroad incumbent
Description

Global pharmaceutical company that co-marketed Cialis® (tadalafil), an approved PDE5 inhibitor for BPH/LUTS. Competes with Cernelle in the broader BPH therapeutics space across multiple geographies.

TypeBroad incumbent
Description

Japanese multinational pharmaceutical company that markets Harnal®/Flomax® (tamsulosin), the leading alpha-blocker for BPH. Competes with Cernelle's Cernilton® in the Japanese urology market where Cernilton is also dominant, making it both a competitor and a complementary therapy partner in BPH treatment paradigms.

TypeBroad incumbent
Description

German generic pharmaceutical company (Sandoz division of Novartis) producing generic tamsulosin, finasteride, and other BPH therapeutics. Competes with Cernelle through low-cost generic alternatives to branded BPH treatments in the German market.

TypeRegional player
Description

Italian pharmaceutical company with plant-based urology products including Serenoa repens formulations. Operates regionally in Italy and selected European markets as a phytopharmaceutical BPH competitor to Cernelle.

10Boehringer Ingelheim
TypeBroad incumbent
Description

Global pharmaceutical company that markets Duodart® (dutasteride/tamsulosin combination) for BPH. Competes with Cernelle in the mainstream BPH treatment market through combination synthetic drug therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ab cernelle

Urological Pharmaceuticalscernelle.se

AB Cernelle is a Swedish pharmaceutical manufacturer, founded in 1953 and now a subsidiary of Dermapharm AG, that develops proprietary pollen-extract APIs (Cernitin T60 and GBX) used in registered drugs such as Cernilton and Cernitol for treating benign prostatic hyperplasia and chronic prostatitis in men, distributed through pharmacies across six countries.

What ab cernelle does

AB Cernelle is a Swedish pharmaceutical company founded in 1953 in Ängelholm, specializing in pollen-based pharmaceutical products for male urological conditions, specifically benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company's core technology is the proprietary Cernitin pollen extraction platform developed in 1956, which produces two active pharmaceutical ingredients (APIs): Cernitin T60 (water-soluble dry extract) and Cernitin GBX (fat-soluble soft extract), derived from machine-harvested pollens from organically grown, specially selected plants. These APIs are the active ingredients in a portfolio of branded products including Cernitol (sold in Sweden since 1959), Cernilton (registered in Japan since 1969), Cernitol Novum, Cernilton A, Shenitong, and Pollstimol, with over 2 billion daily doses administered since 1964 and over 40 published clinical trials supporting clinical use. The products are registered as prescription or OTC medicines in Sweden, Japan, Germany, Hungary, Korea, and China, and target urologists and healthcare professionals who treat men over 50 with BPH and men with chronic nonbacterial prostatitis.

Cernelle operates a single GMP-certified manufacturing facility in Ängelholm, Sweden, certified by the Swedish Medical Products Agency and holding Foreign Manufacturer Accreditation from Japanese Health Authorities. Revenue is generated through pharmaceutical product sales via traditional pharmacy and medical provider distribution channels; pricing is not publicly disclosed. Since December 2021, AB Cernelle has operated as a subsidiary of Dermapharm AG, a German diversified pharmaceutical group, which provides access to broader distribution and pharmaceutical expertise while Cernelle retains its own management team and dedicated Swedish operations. The company employs senior leadership drawn from major pharmaceutical firms including AstraZeneca, Pharmacia, Johnson & Johnson, Recipharm, and Kenvue, reflecting deep GMP and regulatory expertise rather than technology or data science capabilities.

The business model is a niche specialty pharma play built on a single proprietary API platform with multi-decade regulatory standing across multiple jurisdictions. There is no public funding history, no disclosed revenue or ARR, and no SaaS or technology component to the offering; the moat is regulatory and process-based rather than data- or AI-driven. Customer concentration risk is moderate given distribution across six country markets with Japan as the historically largest single market.

ab cernelle firmographics

Firmographics
Name
ab cernelle
Legal name
AB Cernelle
Website
https://cernelle.se
Company type
Private
Founded year
1953
Operating status
Operating
Headcount range
11–50 employees
Short description
AB Cernelle is a Swedish pharmaceutical manufacturer, founded in 1953 and now a subsidiary of Dermapharm AG, that develops proprietary pollen-extract APIs (Cernitin T60 and GBX) used in registered drugs such as Cernilton and Cernitol for treating benign prostatic hyperplasia and chronic prostatitis in men, distributed through pharmacies across six countries.
Ownership category
akta.pro rank

ab cernelle industry classification

Industry
Product category
Urological Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Pollen extract pharmaceuticals
  • Benign prostatic hyperplasia treatment
  • Herbal medicinal products
  • Active pharmaceutical ingredients
  • Urological therapeutics

Where ab cernelle is headquartered

Location

Headquarters

HQ city
Ängelholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

ab cernelle business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Products Sales: Cernelle generates revenue through the sale of registered pharmaceutical products Cernilton® and Cernitol® containing Cernitin™ pollen extracts as active pharmaceutical ingredients. Products are sold as prescription and OTC medicines through pharmacies and medical providers worldwide.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

ab cernelle product offering

Product offering

Core offering

AB Cernelle develops and manufactures pollen-based pharmaceutical products for the treatment of male urological conditions, specifically benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company's core offering centers on proprietary Cernitin™ pollen extracts (Cernitin™ T60 water-soluble and Cernitin™ GBX fat-soluble), which serve as active pharmaceutical ingredients in finished dosage-form products such as Cernilton® and Cernitol® sold globally through pharmacy and medical provider channels.

Product overview

AB Cernelle is a pharmaceutical company specializing in pollen extract-based pharmaceuticals. The core product portfolio centers on Cernitin™ pollen extracts, two active pharmaceutical ingredients (APIs): Cernitin™ T60 (water-soluble, dry extract) and Cernitin™ GBX (fat-soluble, soft extract). These APIs serve as active ingredients in multiple registered pharmaceutical products including Cernilton® (tablet formulation, registered 1969), Cernitol® (sold in Sweden since 1959), Cernitol® Novum, Shenitong®, Cernilton A®, and Pollstimol®. All products are used for treatment of lower urinary tract symptoms (LUTS) caused by benign prostate diseases including benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company operates GMP-certified manufacturing facilities in Sweden.

Differentiator

Problem solved

Functional benefit

Brands

  • Cernitin™: Cernitin™ pollen extracts are the active pharmaceutical ingredients (APIs) manufactured by Cernelle, including Cernitin™ T60 (water soluble dry extract) and Cernitin™ GBX (fat soluble soft extract). These are worldwide registered trademarks belonging to AB Cernelle.
  • Cernilton®
  • Cernitol®

Products and services

  • Cernitin™ T60 Water-soluble, dry pollen extract classified as an active pharmaceutical ingredient (API). Produced from machine-harvested pollens from organically grown, specially selected plants. Used as an API in pharmaceutical products for treating lower urinary tract symptoms caused by benign prostate diseases.
  • Cernitin™ GBX Fat-soluble, soft pollen extract classified as an active pharmaceutical ingredient (API). Produced from machine-harvested pollens from organically grown, specially selected plants. Used as an API in pharmaceutical products for treating lower urinary tract symptoms caused by benign prostate diseases.
  • Cernilton® Tablet formulation pharmaceutical product containing Cernitin™ pollen extracts as active ingredients. Registered in Japan since 1969 for treatment of chronic prostatitis, chronic pelvic pain syndrome (CP/CPPS), and benign prostate hyperplasia. One of only two pharmaceutical drugs registered worldwide to treat chronic prostatitis and CP/CPPS effectively.
  • Cernitol® Pharmaceutical product containing Cernitin™ pollen extracts as active ingredients. Sold in Sweden since 1959 for treatment of chronic prostatitis, chronic pelvic pain syndrome (CP/CPPS), and benign prostate hyperplasia. The Swedish market brand name for the Cernitin™ pollen extract-based product.
  • Cernitol® Novum Cernitin™ pollen extract-based pharmaceutical product for treatment of lower urinary tract symptoms caused by benign prostate diseases. Backed by over 40 clinical studies showing good efficacy and tolerability, positioning it as the best-documented plant-based medicine for prostate problems.
  • Shenitong® Registered pharmaceutical product containing Cernitin™ pollen extracts as the active ingredient, sold in markets where approved by national health authorities.
  • Cernilton A® Registered pharmaceutical product containing Cernitin™ pollen extracts as the active ingredient, sold in markets where approved by national health authorities.
  • Pollstimol® Registered pharmaceutical product containing Cernitin™ pollen extracts as the active ingredient, sold in markets where approved by national health authorities.

Quantifiable outcome

  • Over 40 clinical published trials confirming clinical relevance and efficacy
  • +3 more outcomes

Companies that use ab cernelle

Customer profile

Segments2 records

Ideal customer profiles2 records

ab cernelle technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ab cernelle partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

ab cernelle competitors and assessment

Company assessment

Direct peers

  • Rottapharm Biotech: Italian pharmaceutical company with a strong phytopharmaceutical urology portfolio, including Serenoa repens-based products for BPH. Directly competes with Cernelle as a plant-based BPH specialist in European markets.
  • Apogepha Arzneimittel: German specialty pharmaceutical company focused on urology, marketing both herbal (pumpkin seed extract) and synthetic BPH treatments. Competes with Cernelle in the German-speaking BPH market through similar phytopharmaceutical positioning.
  • Strathmann AG: German herbal pharmaceutical company specializing in urology and a subsidiary of Dermapharm AG (Cernelle's parent). Sells plant-based BPH remedies and other urology products, making it a sister-company peer with overlapping botanical-urology positioning and shared distribution within the Dermapharm portfolio.
  • Pierre Fabre: French pharmaceutical company whose Permixon® (Serenoa repens/saw palmetto extract) is one of the leading plant-based medicines for BPH globally. Directly competes with Cernelle's Cernitol®/Cernilton® in the phytopharmaceutical urology segment and is the most established direct botanical competitor in this indication.

Broad incumbents

  • GlaxoSmithKline: Global pharmaceutical company that previously marketed Avodart® (dutasteride), a 5-alpha-reductase inhibitor for BPH. Competes broadly with Cernelle in the BPH therapeutics market through mainstream synthetic drug offerings.
  • Eli Lilly: Global pharmaceutical company that co-marketed Cialis® (tadalafil), an approved PDE5 inhibitor for BPH/LUTS. Competes with Cernelle in the broader BPH therapeutics space across multiple geographies.
  • Astellas Pharma: Japanese multinational pharmaceutical company that markets Harnal®/Flomax® (tamsulosin), the leading alpha-blocker for BPH. Competes with Cernelle's Cernilton® in the Japanese urology market where Cernilton is also dominant, making it both a competitor and a complementary therapy partner in BPH treatment paradigms.
  • HEXAL (Sandoz): German generic pharmaceutical company (Sandoz division of Novartis) producing generic tamsulosin, finasteride, and other BPH therapeutics. Competes with Cernelle through low-cost generic alternatives to branded BPH treatments in the German market.
  • Boehringer Ingelheim: Global pharmaceutical company that markets Duodart® (dutasteride/tamsulosin combination) for BPH. Competes with Cernelle in the mainstream BPH treatment market through combination synthetic drug therapy.

Regional players

  • IDI Farmaceutici: Italian pharmaceutical company with plant-based urology products including Serenoa repens formulations. Operates regionally in Italy and selected European markets as a phytopharmaceutical BPH competitor to Cernelle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ab cernelle social profiles

Digital presence

ab cernelle compliance and trust

Trust signal

Compliance5 records

ab cernelle financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ab cernelle leadership team

Management profile

Number of profiles

Profiles5 records

ab cernelle funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ab cernelle M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ab cernelle

What does ab cernelle do?

AB Cernelle develops and manufactures pollen-based pharmaceutical products for the treatment of male urological conditions, specifically benign prostatic hyperplasia (BPH) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The company's core offering centers on proprietary Cernitin™ pollen extracts (Cernitin™ T60 water-soluble and Cernitin™ GBX fat-soluble), which serve as active pharmaceutical ingredients in finished dosage-form products such as Cernilton® and Cernitol® sold globally through pharmacy and medical provider channels.

Is ab cernelle a public or private company?

ab cernelle is a private company. It is classified as corporate owned and is currently operating.

When was ab cernelle founded?

ab cernelle was founded in 1953. It employs 11 to 50 people.

Where is ab cernelle based?

ab cernelle is headquartered in Ängelholm, Sweden, in the Europe region.

How does ab cernelle make money?

One revenue line is on record: pharmaceutical Products Sales.

Who are ab cernelle's main competitors?

Direct peers on record are Rottapharm Biotech, Apogepha Arzneimittel, Strathmann AG and Pierre Fabre. Broad incumbents are GlaxoSmithKline, Eli Lilly, Astellas Pharma, HEXAL (Sandoz) and Boehringer Ingelheim. IDI Farmaceutici is listed as a regional player.

Does ab cernelle have an API?

No public API is recorded for ab cernelle.

What industry is ab cernelle in?

ab cernelle's product category is Urological Pharmaceuticals. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales